Logo

Upstate Partners with CXR Biosciences to Develop Drug-Screening Tests

Jun 22, 2005

NEW YORK, June 22 (GenomeWeb News) - A Serologicals subsidiary and CXR Biosciences plan to co-develop a series of in vitro tests to aid in the early-stage drug-discovery process.

 

The subsidiary, Upstate Group, will partner with the Dundee, Scotland-based CXR to develop the drug toxicity and metabolism screens to profile compounds in various cell-based and in vitro assays.

Breaking News
The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.